Aktienanalyse zu Moleculin Biotech Inc (MBRX)MBRXMoleculin Biotech Inc

Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Moleculin Biotech Inc (MBRX) is currently not a good buy due to significant risks despite some recent positive indicators. The current price is $8.87, which is drastically lower than the 52-week high of $253.05, indicating a substantial decline. The RSI is at 61.89, suggesting the stock is nearing overbought territory, while the forward P/E ratio is at 0, indicating uncertainty in future earnings. Furthermore, the company has reported a net income loss of $25,399,000 for Q3 2025, which raises concerns about its financial health. The primary risk is the company's cash position, with only $10.317 million available, which may not be sufficient for ongoing operations and trials, especially given the recent stock plunge of over 25% following clinical trial data.

1 analysts cover MBRX: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 24.33.